Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.72 |
| ▸ | KIT | P10721 | 5/20 | 0.72 |
| ▸ | FLT3 | P36888 | 5/20 | 0.72 |
| ▸ | KDR | P35968 | 4/20 | 0.72 |
| ▸ | LCK | P06239 | 1/20 | 0.72 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.72 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.72 |
| ▸ | EGFR | P00533 | 3/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.57 |
| ▸ | AXL | P30530 | 1/20 | 0.52 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.52 |
| ▸ | MERTK | Q12866 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269680 | 0.89 | MET (0.72) | METKITFLT3KDRLCK | |
| SCHEMBL4818940 | 0.84 | MET (0.79) | METKITFLT3KDRLCK | |
| SCHEMBL4817260 | 0.84 | MET (1.00) | METKITFLT3KDRLCK | |
| SCHEMBL1270142 | 0.83 | MET (0.60) | METKITFLT3KDRLCK | |
| SCHEMBL4820707 | 0.82 | MET (0.77) | METKITFLT3KDRLCK | |
| SCHEMBL4816591 | 0.82 | MET (0.76) | METKITFLT3KDRLCK | |
| SCHEMBL14018100 | 0.82 | MET (0.76) | METKITFLT3KDRLCK | |
| SCHEMBL1269168 | 0.81 | MET (0.71) | METKITFLT3KDRLCK | |
| SCHEMBL1269377 | 0.80 | MET (0.58) | METKITFLT3KDRLCK | |
| SCHEMBL3913677 | 0.79 | MET (0.65) | METAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7880004-B2 | protein tyrosine kinase inhibitors such as 4-(1H-Pyrrolo[2,3-b]pyridin-4-yloxy)-2,5-difluoro-N-(1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridin-3-yl)benzamide, trifluoroacetic acid salt, useful for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-01 | — | — | US | claimed |
| US-20070117802-A1 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-24 | — | — | US | claimed |
| US-7880004-B2 | protein tyrosine kinase inhibitors such as 4-(1H-Pyrrolo[2,3-b]pyridin-4-yloxy)-2,5-difluoro-N-(1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridin-3-yl)benzamide, trifluoroacetic acid salt, useful for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-01 | — | — | US | disclosed |
| US-7880004-B2 | protein tyrosine kinase inhibitors such as 4-(1H-Pyrrolo[2,3-b]pyridin-4-yloxy)-2,5-difluoro-N-(1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridin-3-yl)benzamide, trifluoroacetic acid salt, useful for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-01 | — | — | US | disclosed |
| US-7880004-B2 | protein tyrosine kinase inhibitors such as 4-(1H-Pyrrolo[2,3-b]pyridin-4-yloxy)-2,5-difluoro-N-(1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridin-3-yl)benzamide, trifluoroacetic acid salt, useful for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-01 | — | — | US | disclosed |
| US-20070117802-A1 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-24 | — | — | US | disclosed |
| US-20070117802-A1 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-24 | — | — | US | disclosed |
| US-20070117802-A1 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-24 | — | — | US | disclosed |
| WO-2007035428-A1 | MET KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117802-A1 | Met kinase inhibitors | MET, ERBB2, ABL1 | MET 1/4885KIT 74/4885FLT3 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.